These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30311368)

  • 1. Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels.
    Sbrana F; Bigazzi F; Dal Pino B; Toma M; Ripoli A; Sampietro T
    Ther Apher Dial; 2019 Aug; 23(4):385-386. PubMed ID: 30311368
    [No Abstract]   [Full Text] [Related]  

  • 2. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibitors: A new improvement for health.
    Perelló Camacho E
    Clin Investig Arterioscler; 2019; 31(5):241-243. PubMed ID: 30737073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors.
    Cicero AFG; Toth PP; Fogacci F; Virdis A; Borghi C
    Nutr Metab Cardiovasc Dis; 2019 May; 29(5):527-529. PubMed ID: 30954414
    [No Abstract]   [Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 6. PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies.
    Ruscica M; Watts GF; Sirtori CR
    Eur J Prev Cardiol; 2019 Jun; 26(9):998-1000. PubMed ID: 30845833
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].
    Schettler VJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P; ;
    Internist (Berl); 2016 May; 57(5):511-6. PubMed ID: 27118008
    [No Abstract]   [Full Text] [Related]  

  • 8. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
    Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.
    Hohenstein B; Tselmin S; Bornstein SR; Julius U
    Atheroscler Suppl; 2017 Nov; 30():28-32. PubMed ID: 29096851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.
    Stamerra CA; Di Giosia P; Giorgini P; De Feo M; Grassi D; Ferri C; Sahebkar A
    J Neurosci Res; 2018 May; 96(5):762-764. PubMed ID: 29152786
    [No Abstract]   [Full Text] [Related]  

  • 11. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
    Lappegård KT; Kjellmo CA; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Karlsson H; Hovland A
    Transfus Apher Sci; 2018 Feb; 57(1):91-96. PubMed ID: 29398508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial Hypercholesterolaemia Regression Study and its implications.
    Watts GF
    Lancet; 1995 Apr; 345(8953):807-8. PubMed ID: 7898224
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
    Spitthöver R; Röseler T; Julius U; Heigl F; Schettler VJJ; Kühn R; Leebmann J; Raabe A; Knittel M; Schürfeld C; Moesenthin M; Bernhardt WM; Röseler E; Ketteler M; Heibges A; Klingel R
    J Clin Apher; 2019 Aug; 34(4):423-433. PubMed ID: 30817043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.
    Cokkinos DV; Cokkinos P; Kolovou G
    Arch Cardiovasc Dis; 2019; 112(8-9):455-458. PubMed ID: 31495741
    [No Abstract]   [Full Text] [Related]  

  • 20. A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC).
    Lunegova OS; Mirrakhimov EM
    Atherosclerosis; 2019 Feb; 281():198-199. PubMed ID: 30545666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.